Clinical trial
Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial…
NCT00334958 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00334958 |
|---|---|
| Title | Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures |
| Official title | A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | Placebo, Rufinamide |
| Enrollment | 356 |
| Start date | Feb 13, 2006 |
| Primary completion | May 20, 2009 |
| Completion | May 20, 2009 |
| First posted | Jun 8, 2006 |
| Last update posted | Jun 14, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: